ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.

Shruti U Gandhy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.